AUG 01, 2013
Allergan, Inc.
Cataract/Anterior Segment, Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Neuro-Ophthalmology/Orbit, Ocular Pathology/Oncology, Oculoplastics/Orbit, Pediatric Ophth/Strabismus, Refractive Mgmt/Intervention, Retina/Vitreous, Uveitis
Allergan, Inc., reported a 10.6 percent increase in total product net sales to $1,577.0 million for the second quarter ended June 30, compared to the second quarter of 2012. Net earnings attributable to Allergan were $359.9 million, up 21.7 percent.
"In the second quarter, double digit sales and earnings growth is in line with our long-term growth aspirations," said David E. I. Pyott, Allergan's chairman and chief executive officer. "We are also pleased with further R&D progress with the FDA Advisory Committee's unanimous recommendation for Juvéderm Voluma XC and with the filing of Ozurdex for diabetic macular edema in both the United States and Europe."
For the full year of 2013, Allergan expects total product net sales between $6,050 million and $6,200 million. Alphagan net product sales are expected to be between $450 million and $480 million, Lumigan franchise product net sales between $620 million and $640 million, Restatis between $870 million and $900 million, Botox between $1,940 million and $2,000 million, and Latisse at approximately $110 million.